References
- Alam M.I. (2016): A comparison between the continual reassessment method and D-optimum design for dose finding in phase I clinical trials. Biometrical Letters 53(2): 69-82.
- Atkinson A.C., Fedorov V.V., Herzberg A.M., Zhang R. (2014): Elemental information matrices and optimal experimental design for generalized regression models. Journal of Statistical Planning and Inference 144(1): 81-91.
- Brunier H.C., Whitehead J. (1994): Sample sizes for phase II clinical trials derived from Bayesian decision theory. Statistics in Medicine 13(23-24): 2493-2502.
- Chernoff H. (1953): Locally optimal designs for estimating parameters. The Annals of Mathematical Statistics 24(4): 586-602.
- Heyd J.M., Carlin B.P. (1999): Adaptive design improvements in the continual reassessment method for phase I studies. Statistics in Medicine 18(11): 1307-1321.
- Korn E.L., Midthune D., Chen T.T, Rubinstein L.V., Christian M.C., Simon R.M. (1994): A comparison of two phase I trial designs. Statistics in Medicine 13(18): 1799-1806.
- O’Quigley J. (2002): Continual reassessment designs with early termination. Biostatistics 3(1): 87-99.
- O’Quigley J., Reiner E. (1998): A stopping rule for the continual reassessment method. Biometrika 85(3): 741-748.
- Stallard N. (1998): Sample size determination for phase II clinical trials based on Bayesian decision theory. Biometrics 54(1): 279-294.
- Thall P.F., Russell K.E. (1998): A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 54(1): 251-264.
- Tighiouart M., Rogatko A. (2012): Number of patients per cohort and sample size considerations using dose escalation with overdose control. Journal of Probability and Statistics 2012: Article ID 692725, pp. 16, doi:10.1155/2012/692725.
- Zohar S., Chevret S. (2001): The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Statistics in Medicine 20(19): 2827-2843.
- Zohar S., Latouche A., Taconnet M., Chevret S. (2003): Software to compute and conduct sequential bayesian phase I or II dose-ranging clinical trials with stopping rules. Computer Methods and Programs in Biomedicine 72(2): 117-125.
Language: English
Page range: 17 - 30
Published on: Jun 22, 2018
Published by: Polish Biometric Society
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Related subjects:
© 2018 M. Iftakhar Alam, Mohaimen Mansur, published by Polish Biometric Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.